Key statistics dashboard for Immutep Limited (IMMP). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers.
Stock Data
| Price | $0.33 |
| Market Cap | $48M |
| Enterprise Value | -$1.5M |
| Beta | 2.32 |
| Exchange | NASDAQ |
| Country | AU |
Valuation Multiples
| P/E Ratio | -0.87 |
| Price / Book | 1.13 |
| P/S | 4.76 |
| EV/EBITDA | 0.02 |
| EV/Sales | -0.10 |
| EV/FCF | 0.03 |
| P/FCF | -1.25 |
| Earnings Yield | -119.58% |
| FCF Yield | -83.77% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 84.97% |
| EBIT Margin | -597.44% |
| EBITDA Margin | -582.41% |
| Operating Margin | -597.44% |
| Net Margin | -544.79% |
| Return on Equity | -98.86% |
| Return on Assets | -95.24% |
| Return on Invested Capital | -125.32% |
| Return on Capital Employed | -125.85% |
Financial Health
| Current Ratio | 5.69 |
| Quick Ratio | 5.69 |
| Cash Ratio | 4.86 |
| Debt / Equity | 0.02 |
| Debt / Assets | 1.26% |
| Net Debt / EBITDA | 0.80 |
| Interest Coverage | -1280.92 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 10.76 |
Per-Share Data
| Revenue per share | 0.10 |
| Book Value per share | 0.42 |
| Cash per share | 0.47 |
| FCF per share | -0.38 |
| Tangible Book Value per share | 0.41 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 0.50 |
Related companies: ACHV · ALLO · CABA · CADL · CAPR · EDIT · MREO
Explore sector: Healthcare · Biotechnology
More sections of IMMP: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks